retractable.com (RVP): Price-to-Projected Revenue Ratio

Public company logo of Retractable Tech (RVP)

The growth of government orders for safety syringes and exports to emerging markets define the financial profile of Retractable Technologies (RVP). The forward P/S ratio visualizes market expectations, where 0.50 shapes the current metric. Capital optimization is based on strategic alliances with the US government, while the stability of the B2B ecosystem and strict regulatory standards guarantee the retention of the hospital client base.

Retractable Technologies Inc. - RVP Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for retractable.com (RVP)

Comprehensive company analysis:RVP (Retractable Tech)
Manufactured products of Retractable Technologies, Inc.

This indicator compares current market capitalization with expected annual revenue, allowing investors to track the dynamics of market expectations and the risk of asset overvaluation. By analyzing the forward P/S ratio, one can assess the extent to which the market currently prices in the successful scaling of robotic lines and the implementation of AI control in the production of medical instruments by Retractable Technologies (RVP).

Key competitors

Intuitive - Forward Price-to-Revenue Multiple|Forward P/S Multiple Danaher Corporation DHR|BDX - Price-to-Projected Revenue Ratio|STERIS Group (STE) - Forward Price-to-Revenue Multiple|WST: Forward P/S Multiple|Market Cap to Future Revenue Ratio baxter.com (BAX)|Price-to-Projected Revenue Ratio Masimo|Market Cap to Projected Revenue STVN (Stevanato Group SpA)|Forward Price-to-Revenue Multiple TFX (Teleflex Inc)|Price to Expected Revenue Ratio MMSI|Price-to-Projected Revenue Ratio Envista Holdings NVST|Market Cap to Expected Sales Ratio icumed.com (ICUI)|XRAY - Price-to-Projected Revenue Ratio|Forward Price to Sales LMAT (LeMaitre Vascular Inc)|ATRC: Forward P/S Multiple|Market Cap to Future Revenue Ratio STAAR Surgical Co (STAA)|Forward Price-to-Revenue Multiple NAGE|ZIMV (zimvie.com) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio AngioDynamics (ANGO)|CERS (Cerus Corp.) - Forward Price to Sales|Forward P/S Multiple TKNO (Alpha Teknova Inc)|Forward P/S Multiple Monogram Orthopedics Inc. MGRM|Sharps Tech - Forward P/S Multiple|InfuSystem Holdings (INFU) - Forward Price-to-Revenue Multiple|UTMD (Utah Medical Products, Inc.) - Forward Price-to-Revenue Multiple|KRMD: Price to Expected Revenue Ratio|NYXH (Nyxoah, S.A.) - Forward P/S Multiple|Forward P/S Multiple Microbot Medical, Inc|Forward P/S Multiple PDEX|Price-to-Projected Revenue Ratio ZTEK (zentek.com)|Price-to-Projected Revenue Ratio Elutia ELUT|Milestone Scientific Inc - Price-to-Projected Revenue Ratio|NEXGEL, Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio harvardbioscience.com|FEMY (Femasys Inc.) - Forward Price-to-Revenue Multiple|Meihua Medical Technologies Co., Ltd. - Forward Price to Sales|Forward Price-to-Revenue Multiple POAI|CJMB (Callan JMB Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple ATRI|NURO - Market Cap to Future Revenue Ratio